Education
About Us
Working with TipRanks
Follow Us
Castle Biosciences (CSTL)
NASDAQ:CSTL
Total Valuation
Castle Biosciences has a market cap or net worth of $759.93M. The enterprise value is $680.11M.
Market Cap$759.93M
Enterprise Value$680.11M
Share Statistics
Castle Biosciences has 29,731,197 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding29,731,197
Owned by Insiders2.65%
Owned by Institutions6.71%
Financial Efficiency
Castle Biosciences’s return on equity (ROE) is -0.05 and return on invested capital (ROIC) is -6.85%.
Return on Equity (ROE)-0.05
Return on Assets (ROA)-0.04
Return on Invested Capital (ROIC)-6.85%
Return on Capital Employed (ROCE)-0.08
Revenue Per Employee439.07K
Profits Per Employee-30.81K
Employee Count784
Asset Turnover0.59
Inventory Turnover10.52
Valuation Ratios
The current PE Ratio of Castle Biosciences is ―. Castle Biosciences’s PEG ratio is 0.21.
PE Ratio―
PS Ratio3.28
PB Ratio2.39
Price to Fair Value2.39
Price to FCF39.81
Price to Operating Cash Flow11.65
PEG Ratio0.21
Income Statement
In the last 12 months, Castle Biosciences had revenue of 344.23M and earned -24.16M in profits. Earnings per share was -0.83.
Revenue344.23M
Gross Profit236.35M
Operating Income-42.81M
Pretax Income-29.51M
Net Income-24.16M
EBITDA11.34M
Earnings Per Share (EPS)-0.83
Cash Flow
In the last 12 months, operating cash flow was 64.35M and capital expenditures -36.02M, giving a free cash flow of 28.33M billion.
Operating Cash Flow64.35M
Free Cash Flow28.33M
Free Cash Flow per Share0.95
Dividends & Yields
Castle Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.59
52-Week Price Change27.61%
50-Day Moving Average34.72
200-Day Moving Average27.39
Relative Strength Index (RSI)26.88
Average Volume (3m)447.99K
Important Dates
Castle Biosciences upcoming earnings date is May 11, 2026, After Close (Confirmed).
Last Earnings DateFeb 26, 2026
Next Earnings DateMay 11, 2026
Ex-Dividend Date―
Financial Position
Castle Biosciences as a current ratio of 5.26, with Debt / Equity ratio of 7.84%
Current Ratio5.26
Quick Ratio5.11
Debt to Market Cap0.03
Net Debt to EBITDA-7.04
Interest Coverage Ratio-497.79
Taxes
In the past 12 months, Castle Biosciences has paid -5.36M in taxes.
Income Tax-5.36M
Effective Tax Rate0.18
Enterprise Valuation
Castle Biosciences EV to EBITDA ratio is 92.37, with an EV/FCF ratio of 36.99.
EV to Sales3.04
EV to EBITDA92.37
EV to Free Cash Flow36.99
EV to Operating Cash Flow16.28
Balance Sheet
Castle Biosciences has $299.50M in cash and marketable securities with $36.91M in debt, giving a net cash position of $262.59M billion.
Cash & Marketable Securities$299.50M
Total Debt$36.91M
Net Cash$262.59M
Net Cash Per Share$8.83
Tangible Book Value Per Share$12.81
Margins
Gross margin is 68.66%, with operating margin of -12.44%, and net profit margin of -7.02%.
Gross Margin68.66%
Operating Margin-12.44%
Pretax Margin-8.57%
Net Profit Margin-7.02%
EBITDA Margin3.30%
EBIT Margin-8.55%
Analyst Forecast
The average price target for Castle Biosciences is $48.60, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$48.60
Price Target Upside90.14% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast10.15%
EPS Growth Forecast-295.52%